Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.
Badar T, Foran JM, Bewersdorf JP, Wang YH, Coltoff A, El Kettani M, Shah K, Denis Oliva F, Lin C, Jamy O, Diebold K, Shallis RM, Siddon A, Katkov D, Schoen A, Khan I, Foucar CE, Atallah E, Goldberg AD, Patel AA.
Badar T, et al. Among authors: patel aa.
Br J Haematol. 2025 May 22. doi: 10.1111/bjh.20187. Online ahead of print.
Br J Haematol. 2025.
PMID: 40400334
No abstract available.